虫草益肾颗粒对C-BSA肾病大鼠肾组织GRα及P-gp170影响的研究
|
摘要
目的：观察虫草益肾颗粒对C-BSA所致膜性肾病大鼠肾脏的保护作用,并探讨该方增加激素敏感性的机制。
方法：实验一：将72只雄性SD大鼠,除12只作为空白对照外,其余60只采用多次尾静脉注射阳离子化牛血清白蛋白(C-BSA)的方法进行造模,最后一次尾静脉注射后,收集造模大鼠24h尿液,根据24hUPQ分为模型组、西药对照组、虫草益肾颗粒低、中、高剂量组,每组12只。造模结束后开始灌胃给药,虫草益肾颗粒低、中、高剂量组分别给予中药溶液3.24g/kg/d,6.48g/kg/d,12.96g/kg/d(含颗粒量),西药组给予环孢素A(31.5mg/kg/d)联合醋酸泼尼松混悬液(0.945mg/kg/d)。空白组及模型组给予等体积生理盐水。连续灌胃4周。观察大鼠一般状态、测定24h尿蛋白定量(24hUPQ)；治疗结束麻醉状态下采血检测各组大鼠血清总蛋白(TP)、白蛋白(ALB)、甘油三酯(TG)、胆固醇(CHOL)等生化指标；光镜及电镜观察肾脏组织病理改变。Real Time PCR方法检测各组肾组织中糖皮质激素受体a(GRa)mRNA、多药耐药基因(MDR1)mRNA的表达情况；免疫组化法检测各组肾组织中GRα、MDR1基因表达产物P糖蛋白170(P-gp170)的表达情况。实验二：48只雄性SD大鼠,分为空白组、单纯模型组、激素干预后模型组(简称激素组)、激素干预后中药治疗组(简称激素加中药组),每组12只。其中单纯模型组同实验一方法造模,激素干预后模型组是在单纯模型基础上给予醋酸泼尼松混悬液(6.3mg/kg/d)灌胃,制备经激素干预后的C-BSA肾病大鼠模型。激素加中药组给予虫草益肾颗粒中剂量(6.48g/kg/d)溶液灌胃,其余三组给予等体积生理盐水,连续给药4周。观察大鼠一般状态,24hU PQ,给药结束后麻醉状态下采血检测各组大鼠血清TP.ALB.TG.C HO L等生化指标,光镜及电镜观察肾脏组织病理改变；Real Time PCR方法检测各组肾组织中GRamRNA、MDR1mRNA的表达情况；免疫组化法及Western Blot法检测各组肾组织中GRα、P-gp170的表达情况
结果：(1)模型组大鼠皮毛松散,无光泽,活动少、精神萎靡,足趾皮肤松弛处可观察到水肿,摄食量少,皮毛脱落。虫草益肾颗粒各剂量治疗组大鼠状态明显改善,活动增多、摄食量增加,水肿消退。西药组大鼠水肿消退,但状态不及中药治疗组,且出现死亡。
(2)虫草益肾颗粒各剂量治疗组大鼠的24hUPQ低于模型组(P<0.01)；血清ALB、TP水平高于模型组(P<0.01)；TG.CHOL水平低于模型组(P<0.01)。
(3)激素加中药组大鼠的24hUPQ低于单纯模型组及激素组(P<0.01)；血清ALB、TP水平高于单纯模型组及激素组(P<0.01)；TG、CHOL水平低于单纯模型组及激素组(P<0.01)。
(4)Real Time PCR及免疫组化结果显示,单纯模型组大鼠肾组织中GRα及P-gp170的表达在基因与转录水平上均与空白组无明显差异(P>0.05)。
(5)Real Time PCR.免疫组化及Western Blot结果显示,与空白组相比,激素组大鼠肾组织中GRamRNA以及GRa的表达减少(P<0.01),MDR1mRNA及P-gp170的表达升高(P<0.01)。
(6)Real Time PCR.免疫组化及Western Blot结果显示,与激素组相比,激素加中药组肾组织中GRαmRNA以及GRα表达上调(P<0.01)而MDR1mRNA及P-gp170表达降低(P<0.01)。
结论：(1)虫草益肾颗粒可改善C-BSA肾病大鼠的一般状态,该方面的作用优于西药组。
(2)虫草益肾颗粒可减少C-BSA肾病大鼠蛋白尿,改善低蛋白血症、调节脂质代谢紊乱,并可减轻C-BSA肾病大鼠肾脏病理改变,保护肾小球。
(3)虫草益肾颗粒协同激素治疗C-BSA肾病大鼠起效快,效果显著,较单纯应用激素治疗效果明显,缩短病程。
(4)单纯的C-BSA肾病大鼠模型肾组织中可能不存在GRα及P-gp170表达的改变。
(5)糖皮质激素可能会减少C-BSA肾病大鼠肾组织中GRa的表达,上调P-gp170的表达。
(6)虫草益肾颗粒可增加激素敏感性,其机制可能与上调肾组织中GRα、下调P-gp170的表达有关
Objective:
To investigate the effect of ChongCaoYiSheng granule on the membranous nephropathy(MN) induced by cationic bovine serum albumin(C-BSA) in rats,and to explore the mechanism of increased sensitivity to glucocorticoid.
Methods:
Experiment One:Except12rats were the comparison group,72wistar rats were divided into5groups according to24hUPQ:model group, western medicine group, ChongCaoYiSheng granule low dose group, medium dose group, and high dose group. Rats model were induced by repeatedly tail vein injection C-BSA. The western medicine group were fed with suspension liquid consisted of Prednisone acetate and cyclosporine A. While ChongCaoYiSheng group was fed with traditional Chinese medicine solution, and the normal group was fed with normal saline with the same volume as the western medicine group. Every group was fed one time one day for4weeks. The general conditions of rats were dynamically observed during treatment, and the24hUPQ were determined before and after treatment. ALB, TP, TG, and CHOL level of rats blood serum were measured after treatment which was taken from the anaesthetic rats. All rats were killed after4weeks, and pathological changes were observed by light microscopy and electron microscope. RealTime PCR was used to detect the expression of GRamRNA and MDRlmRNA. Immunohistochemistry and Western Blot method were used to examine the expression of GRa and P-gp170.
Experiment Two:48wistar rats were randomly divided into4groups:normal group, pure model group, model group after hormonal intervention (glucocorticoid group), Chinese medicine treatment model after hormonal intervention (glucocorticoid combined with Chinese medicine group), with12rats in every group. The pure model group was founded by the same method as in the experiment one. The glucocorticoid group was founded by feeding the pure model group with Prednisone acetate suspension liquid (6.3mg/kg/d), by which the glucocorticoid C-BSA rats model are founded. The glucocorticoid combined with Chinese medicine group was fed with ChongCaoYiSheng medium dose solution (3.6g/kg/d). The normal group, pure model group and glucocorticoid group was fed with the same volume normal saline. Every group were fed one time each day for4weeks. The general conditions of rats were dynamically observed during treatment, and the24hUPQ were determined before and after treatment. After4weeks, pathological changes were observed by light microscopy and electron microscope, the same indexes (ALB, TP, TG and CHOL level) as experiment one were measured, and the same detecting measures (such as RealTime PCR, Immunohistochemistry and Western Blot method) were also used to examine the expression of GRamRNA, MDR1mRNA, GRa and P-gp170.
Results:
(1) The fur of the model group rats were loose and lackluster and they showed declining activity, listlessness, and lack of food intakes. There were edema and fur shedding which were observed in the toe slack skin of the model rats. The status of rats in ChongChao YiSheng granule low, medium, and high dose group were ameliorative distinctly, which demonstrated more activity, eating more and their edema were faded. The edema of rats in western medicine group were faded; however their status could not compete with those in Chinese medicine group, and someone were dead.
(2) The24hUPQ of rats in ChongChao YiSheng granule group are lower than that model group (P<0.01); the ALB and TP level of blood serum were higher than that of model group (P<0.01); and the TG and CHOL level of rats were less than that model group (P<0.01);
(3) The24hUPQ of rats with glucocorticoid combined with Chinese medicine group were lower than that of model group and glucocorticoid group (P<0.01); But the TG, CHOL level of rats were below that of the model group and glucocorticoid group (P<0.01);
(4) The results of Real Time PCR and Immunohistochemical results indicated that the GRa and P-gp170expressions level of rats in model group were not obviously discrepancy from normal group (P>0.05);
(5) Comparing to normal group, the results of Real Time PCR, Immunohistochemical and Western Blot indicated that the GRa expressions in nail tissue of rats in glucocorticoid group were decreased (P<0.01), whereas the expressions of P-gpl70were raised (P<0.01):
(6) Comparing to glucocorticoid group, the results of Real Time PCR, Immunohistochemical and Western Blot indicated that the GRa expressions in nail tissue of rats in glucocorticoid combined with Chinese medicine group were raised (P<0.01), nevertheless the expressions of P-gp170were reduced (P<0.01);
Conclusion:
(1) ChongCaoYiSheng granule can ameliorate the status of C-BSA rats and improve their quality of life. Its effect in this respect is better than that of western medicine group;
(2) ChongCaoYiSheng granule can reduce the albuminuria of C-BSA rats, meliorate Hypoproteinemia, and adjust disturbance of lipid metabolism. At the same time, it can alleviate the nephritic pathological changes of C-BSA rats and protect Glomerulus;
(3) The effect of ChongCaoYiSheng granule combined with glucocorticoid treatment on C-BSA rats were fast and significant. It shortens the treating time and has better treatment effect than treatment only with glucocorticoid treatment;
(4) Possibly, there were not changes of GRa and P-gp170expressions in renal tissue of the simple C-BSA model rats;
(5) Glucocorticoid can reduce the GRa expressions in renal tissue of C-BSA rats and raise the expressions of P-gp170;
(6) ChongCaoYiSheng paticle can enhance the glucocorticoid sensitive and improve the GC resistance of RNS. The mechanism may have to do with the up-regulation GRa expressions and down regulation P-gp170expressions of renal tissue.
方法：实验一：将72只雄性SD大鼠,除12只作为空白对照外,其余60只采用多次尾静脉注射阳离子化牛血清白蛋白(C-BSA)的方法进行造模,最后一次尾静脉注射后,收集造模大鼠24h尿液,根据24hUPQ分为模型组、西药对照组、虫草益肾颗粒低、中、高剂量组,每组12只。造模结束后开始灌胃给药,虫草益肾颗粒低、中、高剂量组分别给予中药溶液3.24g/kg/d,6.48g/kg/d,12.96g/kg/d(含颗粒量),西药组给予环孢素A(31.5mg/kg/d)联合醋酸泼尼松混悬液(0.945mg/kg/d)。空白组及模型组给予等体积生理盐水。连续灌胃4周。观察大鼠一般状态、测定24h尿蛋白定量(24hUPQ)；治疗结束麻醉状态下采血检测各组大鼠血清总蛋白(TP)、白蛋白(ALB)、甘油三酯(TG)、胆固醇(CHOL)等生化指标；光镜及电镜观察肾脏组织病理改变。Real Time PCR方法检测各组肾组织中糖皮质激素受体a(GRa)mRNA、多药耐药基因(MDR1)mRNA的表达情况；免疫组化法检测各组肾组织中GRα、MDR1基因表达产物P糖蛋白170(P-gp170)的表达情况。实验二：48只雄性SD大鼠,分为空白组、单纯模型组、激素干预后模型组(简称激素组)、激素干预后中药治疗组(简称激素加中药组),每组12只。其中单纯模型组同实验一方法造模,激素干预后模型组是在单纯模型基础上给予醋酸泼尼松混悬液(6.3mg/kg/d)灌胃,制备经激素干预后的C-BSA肾病大鼠模型。激素加中药组给予虫草益肾颗粒中剂量(6.48g/kg/d)溶液灌胃,其余三组给予等体积生理盐水,连续给药4周。观察大鼠一般状态,24hU PQ,给药结束后麻醉状态下采血检测各组大鼠血清TP.ALB.TG.C HO L等生化指标,光镜及电镜观察肾脏组织病理改变；Real Time PCR方法检测各组肾组织中GRamRNA、MDR1mRNA的表达情况；免疫组化法及Western Blot法检测各组肾组织中GRα、P-gp170的表达情况
结果：(1)模型组大鼠皮毛松散,无光泽,活动少、精神萎靡,足趾皮肤松弛处可观察到水肿,摄食量少,皮毛脱落。虫草益肾颗粒各剂量治疗组大鼠状态明显改善,活动增多、摄食量增加,水肿消退。西药组大鼠水肿消退,但状态不及中药治疗组,且出现死亡。
(2)虫草益肾颗粒各剂量治疗组大鼠的24hUPQ低于模型组(P<0.01)；血清ALB、TP水平高于模型组(P<0.01)；TG.CHOL水平低于模型组(P<0.01)。
(3)激素加中药组大鼠的24hUPQ低于单纯模型组及激素组(P<0.01)；血清ALB、TP水平高于单纯模型组及激素组(P<0.01)；TG、CHOL水平低于单纯模型组及激素组(P<0.01)。
(4)Real Time PCR及免疫组化结果显示,单纯模型组大鼠肾组织中GRα及P-gp170的表达在基因与转录水平上均与空白组无明显差异(P>0.05)。
(5)Real Time PCR.免疫组化及Western Blot结果显示,与空白组相比,激素组大鼠肾组织中GRamRNA以及GRa的表达减少(P<0.01),MDR1mRNA及P-gp170的表达升高(P<0.01)。
(6)Real Time PCR.免疫组化及Western Blot结果显示,与激素组相比,激素加中药组肾组织中GRαmRNA以及GRα表达上调(P<0.01)而MDR1mRNA及P-gp170表达降低(P<0.01)。
结论：(1)虫草益肾颗粒可改善C-BSA肾病大鼠的一般状态,该方面的作用优于西药组。
(2)虫草益肾颗粒可减少C-BSA肾病大鼠蛋白尿,改善低蛋白血症、调节脂质代谢紊乱,并可减轻C-BSA肾病大鼠肾脏病理改变,保护肾小球。
(3)虫草益肾颗粒协同激素治疗C-BSA肾病大鼠起效快,效果显著,较单纯应用激素治疗效果明显,缩短病程。
(4)单纯的C-BSA肾病大鼠模型肾组织中可能不存在GRα及P-gp170表达的改变。
(5)糖皮质激素可能会减少C-BSA肾病大鼠肾组织中GRa的表达,上调P-gp170的表达。
(6)虫草益肾颗粒可增加激素敏感性,其机制可能与上调肾组织中GRα、下调P-gp170的表达有关
Objective:
To investigate the effect of ChongCaoYiSheng granule on the membranous nephropathy(MN) induced by cationic bovine serum albumin(C-BSA) in rats,and to explore the mechanism of increased sensitivity to glucocorticoid.
Methods:
Experiment One:Except12rats were the comparison group,72wistar rats were divided into5groups according to24hUPQ:model group, western medicine group, ChongCaoYiSheng granule low dose group, medium dose group, and high dose group. Rats model were induced by repeatedly tail vein injection C-BSA. The western medicine group were fed with suspension liquid consisted of Prednisone acetate and cyclosporine A. While ChongCaoYiSheng group was fed with traditional Chinese medicine solution, and the normal group was fed with normal saline with the same volume as the western medicine group. Every group was fed one time one day for4weeks. The general conditions of rats were dynamically observed during treatment, and the24hUPQ were determined before and after treatment. ALB, TP, TG, and CHOL level of rats blood serum were measured after treatment which was taken from the anaesthetic rats. All rats were killed after4weeks, and pathological changes were observed by light microscopy and electron microscope. RealTime PCR was used to detect the expression of GRamRNA and MDRlmRNA. Immunohistochemistry and Western Blot method were used to examine the expression of GRa and P-gp170.
Experiment Two:48wistar rats were randomly divided into4groups:normal group, pure model group, model group after hormonal intervention (glucocorticoid group), Chinese medicine treatment model after hormonal intervention (glucocorticoid combined with Chinese medicine group), with12rats in every group. The pure model group was founded by the same method as in the experiment one. The glucocorticoid group was founded by feeding the pure model group with Prednisone acetate suspension liquid (6.3mg/kg/d), by which the glucocorticoid C-BSA rats model are founded. The glucocorticoid combined with Chinese medicine group was fed with ChongCaoYiSheng medium dose solution (3.6g/kg/d). The normal group, pure model group and glucocorticoid group was fed with the same volume normal saline. Every group were fed one time each day for4weeks. The general conditions of rats were dynamically observed during treatment, and the24hUPQ were determined before and after treatment. After4weeks, pathological changes were observed by light microscopy and electron microscope, the same indexes (ALB, TP, TG and CHOL level) as experiment one were measured, and the same detecting measures (such as RealTime PCR, Immunohistochemistry and Western Blot method) were also used to examine the expression of GRamRNA, MDR1mRNA, GRa and P-gp170.
Results:
(1) The fur of the model group rats were loose and lackluster and they showed declining activity, listlessness, and lack of food intakes. There were edema and fur shedding which were observed in the toe slack skin of the model rats. The status of rats in ChongChao YiSheng granule low, medium, and high dose group were ameliorative distinctly, which demonstrated more activity, eating more and their edema were faded. The edema of rats in western medicine group were faded; however their status could not compete with those in Chinese medicine group, and someone were dead.
(2) The24hUPQ of rats in ChongChao YiSheng granule group are lower than that model group (P<0.01); the ALB and TP level of blood serum were higher than that of model group (P<0.01); and the TG and CHOL level of rats were less than that model group (P<0.01);
(3) The24hUPQ of rats with glucocorticoid combined with Chinese medicine group were lower than that of model group and glucocorticoid group (P<0.01); But the TG, CHOL level of rats were below that of the model group and glucocorticoid group (P<0.01);
(4) The results of Real Time PCR and Immunohistochemical results indicated that the GRa and P-gp170expressions level of rats in model group were not obviously discrepancy from normal group (P>0.05);
(5) Comparing to normal group, the results of Real Time PCR, Immunohistochemical and Western Blot indicated that the GRa expressions in nail tissue of rats in glucocorticoid group were decreased (P<0.01), whereas the expressions of P-gpl70were raised (P<0.01):
(6) Comparing to glucocorticoid group, the results of Real Time PCR, Immunohistochemical and Western Blot indicated that the GRa expressions in nail tissue of rats in glucocorticoid combined with Chinese medicine group were raised (P<0.01), nevertheless the expressions of P-gp170were reduced (P<0.01);
Conclusion:
(1) ChongCaoYiSheng granule can ameliorate the status of C-BSA rats and improve their quality of life. Its effect in this respect is better than that of western medicine group;
(2) ChongCaoYiSheng granule can reduce the albuminuria of C-BSA rats, meliorate Hypoproteinemia, and adjust disturbance of lipid metabolism. At the same time, it can alleviate the nephritic pathological changes of C-BSA rats and protect Glomerulus;
(3) The effect of ChongCaoYiSheng granule combined with glucocorticoid treatment on C-BSA rats were fast and significant. It shortens the treating time and has better treatment effect than treatment only with glucocorticoid treatment;
(4) Possibly, there were not changes of GRa and P-gp170expressions in renal tissue of the simple C-BSA model rats;
(5) Glucocorticoid can reduce the GRa expressions in renal tissue of C-BSA rats and raise the expressions of P-gp170;
(6) ChongCaoYiSheng paticle can enhance the glucocorticoid sensitive and improve the GC resistance of RNS. The mechanism may have to do with the up-regulation GRa expressions and down regulation P-gp170expressions of renal tissue.
引文
[1]Bamberger C M, Bamberger A M, de Castro M, et al. Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans[J]. J Clin Invest,1995,95(6):2435-2441.
[2]Ross D D. Novel mechanisms of drug resistance in leukemia[J]. Leukemia,2000,14(3):467-473.
[3]Farrell R J,Menconi M J.Keates A C,et al.P-glycoprotein-170 inhibition significantly reduces cortisol and ciclosporin efflux from human intestinal epithelial cells and T lymphocytes[J]. Aliment Pharmacol Ther,2002,16(5):1021-1031.
[4]Stachowski J, Zanker C B, Runowski D, et al. Resistance to therapy in primary nephrotic syndrome:effect of MDR1 gene activity[J]. Pol Merkur Lekarski,2000,8(46):218-221.
[5]Wasilewska A, Zoch-Zwierz W, Pietruczuk M. Expression of multidrug resistance P-glycoprotein on lymphocytes from nephrotic children treated with cyclosporine A and ACE-inhibitor[J]. Eur J Pediatr, 2007,166(5):447-452.
[6]郭向东,邵朝弟,王小琴.邵朝弟教授治疗难治性肾病综合征的临证经验[J].光明中医,2013,28(12)：2502-2504.
[7]武俊斌,顾秀琰.戴恩来教授治疗难治性肾病综合征经验[J].亚太传统医药,2007,27(1)：52-54.
[8]夏海岩,符丹,潘公益,等.沈丕安教授运用金雀根汤治疗难治性肾病综合征的疗效观察[J].四川中医,2013,31(7)：82-84.
[9]李宁,宁静.补肾固精方治疗小儿难治性肾病综合征54例疗效观察[J].中国中西医结合儿科学,2013,5(4)：301-302.
[10]杨少延,庄花.宣肺利水扶正汤治疗难治性肾病综合征水肿28例[J].陕西中医,2012,33(8)：970-971.
[11]雷宏强,丁晓炼,徐薇,等.黄芪五苓散联合激素治疗难治性肾病 综合征疗效观察[J].陕西中医,2012,33(8)：973-974.
[12]孙瑞涛,杨毅勇.补阳还五汤治疗难治性肾病综合征的疗效评价[J].同济大学学报(医学版),2013,34(4)：104-107.
[13]魏连波,陈严文.叶任高教授治疗常复发性肾病综合征的经验[J].中国中西医结合肾病杂志,2011,12(11)：949-950.
[14]张恩,汤水福.汤水福教授标本论治难治性肾病综合征临证撷菁[J].中国中西医结合肾病杂志,2013,14(9)：817-818.
[15]傅玉素,倪青.时振声教授治疗难治性肾病综合征的经验[J].新中医,1998,30(11)：8-9.
[16]刘玉宁,杜兰屏,邓跃毅.陈以平教授治疗膜性肾病的经验[J].中国中西医结合肾病杂志,2004,5(3)：131-132.
[17]董保华,李绍华,袁平.叶传蕙教授治疗难治性肾病综合征经验[J].山西中医,2008,24(8)：6-8.
[18]杨倩春.杨霓芝教授治疗难治性肾病综合征的临床经验[J].中国中西医结合肾病杂志,2003,4(9)：500-502.
[19]沈莲莉,李交,郑蓉,等.灸药并用对难治性肾病综合征患者血清IL-6与IL-8的影响[J].世界中西医结合杂志,2013,8(6)：582-584.
[20]张雪荣,李云海.肾敷灵外敷配合雷公藤多甙对难治性肾病大鼠肾组织炎症因子NF-κB及TGF-β的影响[J].中国中医药现代远程教育2014,12(2)：152-154.
[21]赵学兰,李香玲,郭民,等.益气活血补肾方对难治性肾病综合征患者临床疗效及T淋巴细胞亚群、细胞因子的影响[J].中成药2013,35(8)：1637-1640.
[22]Durkan A, Hodson E M, Willis N S, et al. Non-corticosteroid treatment for nephrotic syndrome in children[J]. the Cochrane library, 2007.
[23]Davutoglu M, Ece A, Bilici M, et al. Steroid Responsiveness of Children with Idiopathic Nephrotic Syndrome in Southeastern Region of Turkey[J]. Renal Failure,2007,29(7):855-859.
[24]McCollum A K, TenEyck C J, Stensgard B, et al. P-Glycoprotein- mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response[J]. Cancer research,2008,68(18):7419-7427.
[25]Palmer S C, Nand K, Strippoli G F. Interventions for minimal change disease in adults with nephrotic syndrome[J]. Cochrane Database Syst Rev,2008,1.
[26]Bai Y, Liu W, Guo Q, et al. Screening for urinary biomarkers of steroid-resistant nephrotic syndrome in children[J]. Experimental and therapeutic medicine,2013,5(3):860-864.
[27]何庆南.糖皮质激素受体亚型与糖皮质激素抵抗关系的研究进展[J].国外医学.泌尿系统分册,2001,21(6)：281-282.
[28]王德杰,刘兴国,张东.糖皮质激素受体的研究进展[J].现代生物医学进展,2010,10(8)：1592-1594.
[29]Stahn C, Lowenberg M, Hommes D W, et al. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists[J]. Molecular and cellular endocrinology,2007,275(1):71-78.
[30]Lewis-Tuffin L J, Cidlowski J A. The physiology of human glucocorticoid receptor beta (hGRbeta) and glucocorticoid resistance[J]. Ann N Y Acad Sci,2006,1069:1-9.
[31]何小解,易著文,党西强,等.GR β在原发性肾病综合征患儿糖皮质激素耐药中的作用[J].中华儿科杂志,2005,43(2)：109-112.
[32]何庆南,易著文,何小解,等.GR β在肾病综合征患儿中的表达及影响因素研究[J].中国病理生理杂志,2002,18(9)：19-22.
[33]邱玲,封其华,赵惠君.原发性肾病综合征患儿外周血GR a、GRβ的表达及临床意义[J].临床儿科杂志,2012,30(4)：332-335.
[34]许冬梅,施惠英,李鹤英,等.原发性肾病综合征患者淋巴细胞糖皮质激素受体及基因测定的意义[J].山东大学学报(医学版),2002,40(4)：297-299.
[35]Hurley D M, Accili D, Stratakis C A, et al. Point mutation causing a single amino acid substitution in the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance[J]. J Clin Invest,1991,87(2):680-686.
[36]Lee Y M, Fujiwara J, Munakata Y, et al. A mutation of the glucocorticoid receptor gene in patients with systemic lupus erythematosus[J]. Tohoku J Exp Med,2004,203(2):69-76.
[37]Charmandari E, Raji A, Kino T, et al. A novel point mutation in the ligand-binding domain (LBD) of the human glucocorticoid receptor (hGR) causing generalized glucocorticoid resistance:the importance of the C terminus of hGR LBD in conferring transactivational activity[J]. J Clin Endocrinol Metab,2005,90(6):3696-3705.
[38]Charmandari E, Kino T, Ichijo T, et al. Functional characterization of the natural human glucocorticoid receptor (hGR) mutants hGRalphaR477H and hGRalphaG679S associated with generalized glucocorticoid resistance[J]. J Clin Endocrinol Metab, 2006,91(4):1535-1543.
[39]Orbak Z. Glucocorticoid resistance[J]. Biochemistry (Mosc), 2006,71(10):1073-1081.
[40]叶建伟,丁洁,黄建萍,等.糖皮质激素受体基因多态性与肾病综合征患儿激素耐药相关性探讨[J].中华儿科杂志,2003,41(9)：25-29.
[41]赵峰,遆新宇,蔡累,等.糖皮质激素受体基因G679S多态性与激素抵抗型哮喘的相关性[J].第四军医大学学报,2009,30(6)：541-544.
[42]赵峰,蔡累,遆新宇,等.糖皮质激素受体基因R477H多态性与激素抵抗型哮喘的相关性[J].临床肺科杂志,2009,14(5)：597-599.
[43]赵峰,刘颖格,遆新宇,等.糖皮质激素受体基因D641V多态性与激素抵抗型哮喘的相关性[A].中国生理学会第23届全国会员代表大会暨生理学学术大会论文摘要文集[c].中国生理学会第23届全国会员代表大会暨生理学学术大会.2010.中国陕西西安：284.
[44]Kang K I, Meng X, Devin-Leclerc J, et al. The molecular chaperone Hsp90 can negatively regulate the activity of a glucocorticosteroid-dependent promoter[J]. Proc Natl Acad Sci USA, 1999,96(4):1439-1444.
[45]欧阳涓,姜傥,谭敏,等.HSP90在原发性肾病综合征发生和治疗中的意义[J].中山大学学报(医学科学版),2006,27(6)：661-666.
[46]Pace T W,Hu F,Miller A H.Cytokine-effects on glucocorticoid receptor function:relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression[J].Brain Behav Immun,2007,21(1):9-19.
[47]黄文彦.原发性肾病综合征糖皮质激素耐药机制研究进展[J].实用儿科临床杂志,2008,23(17)：1315-1318.
[48]Juliano R L,Ling V.A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants[J].Biochim Biophys Acta,1976,455(1):152-162.
[49]Funaki S,Takahashi S.Wada N,et al.Multiple drug-resistant gene 1 in children with steroid-sensitive nephrotic syndrome[J].Pediatr Int,2008,50(2):159-161.
[50]付强,封其华,宋晓翔,等.原发.性肾病综合征患儿外周血单个核细胞多药耐药基因1及P-糖蛋白170的表达[J].实用儿科临床杂志,2010,25(5)：342-344.
[51]Leslie E M,Deeley R G,Cole S P.Multidrug resistance proteins:role of P-glycoprotein, MRP1,MRP2,and BCRP(ABCG2) n tissue defense[J].Toxicol Appl Pharmacol,2005,204(3):216-237.
[52]Mark P J,Waddell B J.P-glycoprotein restricts access of cortisol and dexamethasone to the glucocorticoid receptor in placental BeWo cells[J].Endocrinology,2006,147(11):5147-5152.
[53]王清,刘倩,张学梅.P-糖蛋白及其逆转肿瘤细胞多药耐药性的研究进展[J].中国执业药师,2013,10(3)：33-36.
[54]Hutson J R,Koren G,Matthews S G.Placental P-glycoprotein and breast cancer resistance protein:influence of polymorphisms on fetal drug exposure and physiology[J].Placenta,2010,31 (5):351-357.
[55]闻镍,张双庆,朱凌,等.P-糖蛋白最新研究进展[J].中国药事,2011,25(7)：718-723.
[56]关凤军,易著文,何小解,等.肾病综合征患儿肾组织P-糖蛋白170表达的研究[J].中国实用儿科杂志,2007,22(10)：780-782.
[57]聂吴,王晖.P糖蛋白在不同组织中的分布与功能研究进展[J].广东药学院学报,2012,28(4)：456-460.
[58]Tosi P,Madoulet C.Nicolau C,et al.Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers[Z].Google Patents,2013.
[59]Campone M, Vavasseur F,Le Cabellec M T,et al.Induction of chemoresistance in HL-60 cells concomitantly causes a resistance to apoptosis and the synthesis of P-glycoprotein[J].Leukemia, 2001,15(9):1377-1387.
[60]Mantovani I,Cappellini A,Tazzari P L,et al.Caspase-dependent cleavage of 170-kDa P-glycoprotein during apoptosis of human T-lymphoblastoid CEM cells[J].J Cell Physiol,2006,207(3):836-844.
[61]Ruefli A A,Bernhard D,TaintonKM,et al.Suberoylanilide hydroxamic acid(SAHA) overcomes multidrug resistance and induces cell death in P glycoprotein-expressing cells[J].International journal of cancer, 2002,99(2):292-298.
[62]Jafar T,Prasad N.Agarwal V,et al.MDR-1 gene polymorphisms in steroid-responsive versus steroid-resistant nephrotic syndrome in children[J].NephrologyDialysis Transplantation,2011,26(12):3968-3974.
[63]关凤军,易著文,党西强,等.原发性肾病综合征患儿外周血单个核细胞膜P-糖蛋白170表达的意义[J].实用儿科临床杂志,2011,26(5)：322-324.
[64]关凤军,易著文,党西强,等.肾病综合征患儿外周血单个核细胞内地塞米松浓度与细胞膜表面P-糖蛋白170表达的相关性研究[J].中国循证儿科杂志,2009,4(2)：85-90.
[65]付强,封其华,宋晓翔,等.P-糖蛋白170在原发性肾病综合征患儿糖皮质激素耐药中的作用[J].临床儿科杂志,2010,28(4)：334-337.
[66]王倩涵.阿霉素肾病大鼠MDR1及P-gp170的表达与意义[D].苏州大 学,2013.
[67]Fuchshuber A,Jean G,Gribouval O,et al.Mapping a gene (SRN1) to chromosome 1q25-q31 in idiopathic nephrotic syndrome confirms a distinct entity of autosomal recessive nephrosis[J].Hum Mol Genet, 1995,4(11):2155-2158.
[68]Caridi G.Bertelli R.Carrea A,et al.Prevalence,genetics,and clinical features of patients carrying podocin mutations in steroid-resistant nonfamilial focal segmental glomerulosclerosis[J].J Am Soc Nephrol,2001,12(12):2742-2746.
[69]Karle S M,Uetz B,Ronner V,et al.Novel mutations in NPHS2 detected in both familial and sporadic steroid-resistant nephrotic syndrome[J].J Am Soc Nephrol,2002,13(2):388-393.
[70]Ruf R G,Lichtenberger A,Karle S M,et al.Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome[J].J Am Soc Nephrol,2004,15(3):722-732.
[71]周国平,郭怡清.人类白细胞抗原对肾病综合征临床过程的预测价值[J].中华儿科杂志,1995,33(6)：358-360.
[72]张毓文,林琳,刘晓荣,等.小儿原发性肾病综合征的临床类型与HLA的相关性[J].中华肾脏病杂志,1999,15(3)：52-53.
[73]Attila G,Noyan A,Karabay B A,et al.Apolipoprotein E polymorphism in childhood nephrotic syndrome[J]. Pediatr Nephrol,2002,17(5):359-362.
[74]Hori C,Hiraoka M.Yoshikawa N,et al.Significance of ACE genotypes and medical treatments in childhood focal glomerulosclerosis[J].Nephron,2001,88(4):313-319.
[75]于思明,郭丹丹,宋立群.虫草肾茶方治疗慢性肾衰竭42例临床观察[J].中医药学报,2007,35(06)：44-46.
[76]宋立群,金丽霞,宋业旭.虫草肾茶胶囊治疗糖尿病肾病的临床研究[J].中华中医药学刊,2009,27(04)：679-681.
[77]宋立群,代丽娟.虫草肾茶方对慢性肾衰竭非透析患者微炎症状态的 改善作用[J].中国中西医结合肾病杂志,2008,9(9)：829-831.
[78]于思明,宋立群,郭丹丹,等.虫草‘益肾颗粒治疗维持性血液透析患者微炎症状态临床研究[J].辽宁中医杂志,2013,40(7)：1384-1385.
[79]徐艳秋,宋立群.虫草肾茶方治疗慢性肾脏病不同阶段的临床疗效观察[J].中国中西医结合肾病杂志,2007,8(7)：415-416.
[80]裴春鹏.虫草肾茶胶囊对糖尿病肾病大鼠TGF-β/Smads信号通路影响的实验研究[D].黑龙江中医药大学,2009.
[81]宋立群,金丽霞,宋业旭.虫草肾茶胶囊对肾小球系膜细胞增殖的影响[J].中医药学报,2009,37(3)：21-23.
[82]宋立群,金丽霞,宋业旭.虫草肾茶胶囊对肾小球系膜细胞增殖及分泌Ⅳ型胶原的影响[J].中华中医药学刊,2009,27(9)：1811-1813.
[83]Eddy A A.Plasminogen activator inhibitor-1 and the kidney[J]. Am J Physiol Renal Physiol,2002,283(2):F209-F220.
[84]Schnaper H W.Balance between matrix synthesis and degradations determinant of glomerulosclerosis[J].Pediatr Nephrol,1995,9(1):104-111.
[85]金丽霞,宋立群,马艳春,等.虫草肾茶胶囊对人肾小球系膜细胞TGF-β_1mRNA及PAI-1mRNA表达的影响[J].山西中医,2011,27(5)：44-46.
[86]金丽霞,宋立群,宋业旭.虫草肾茶胶囊对人肾小球系膜细胞分泌转化生长因子β1及细胞外基质的影响[J].中国临床保健杂志,2011,14(3)：287-289.
[87]徐艳秋,宋立群,须冰,等.虫草肾茶对慢性肾衰竭大鼠足细胞中巢蛋白的影响[J].上海中医药杂志,2008,42(10)：73-76.
[88]马晓鹏,宋立群,于思明,等.虫草肾茶颗粒对单侧输尿管结扎大鼠肾间质纤维化模型CTGFmRNA的影响[J].中国临床保健杂志,2010,13(3)：271-274.
[89]于思明,郭丹丹,马艳春,等.虫草益肾颗粒对5/6肾切除大鼠残肾组织α-平滑肌肌动蛋白表达的影响[J].中国临床保健杂志,2010,13(3)：283-285.
[90]宋立群,于思明,郭丹丹,等.虫草肾茶胶囊对5/6肾切除大鼠残肾组织 MMP-2与TIMP-1表达的影响[J].辽宁中医杂志,2009,36(11)：1860-1862.
[91]宋立群,于思明,郭丹丹,等.虫草肾茶胶囊对肾小球硬化早期模型大鼠细胞外基质积聚的影响[J].中国临床保健杂志,2009,12(4)：397-399.
[92]宋立群,于思明,郭丹丹,等.虫草肾茶胶囊对肾小球硬化早期模型大鼠肾脏组织形态学的影响[J].中华中医药学刊,2009,27(10)：2037-2040.
[93]Border W A,Harry J W,Kamil E S,et al.Induction of membranous nephropathy in rabbits by administration of an exogenous cationic antigen:demonstration of a pathogenic role for electrical charge[J].Journal of Clinical Investigation,1982,69(2):451-461.
[94]陈永兴,张秋业.激素耐药型肾病综合征发病机制及治疗对策研究进展[J].实用儿科临床杂志,2006,21(19)：1346-1348.
[95]邢昌赢.KDIGO指南解读：特发性膜性肾病治疗[J].中国实用内科杂志,2012,32(12)：928-931.
[96]刘伏友.蛋白尿致肾小管间质纤维化的机制及防治[J].中华肾脏病杂志,2006,22(5)：258-260.
[97]Theilig F.Spread of glomerular to tubulointerstitial disease with a focus on proteinuria[J].Annals of Anatomy-Anatomischer Anzeiger, 2010,192(3):125-132.
[98]于思明.虫草肾茶胶囊对肾小球硬化模型大鼠ECM积聚与TIMP-1mRNA表达的影响[D].黑龙江中医药大学,2008.
[99]Demant T,Mathes C,Gutlich K,et al.A simultaneous study of the metabolism of apolipoprotein B and albumin in nephrotic patients[J]. Kidney Int,1998,54(6):2064-2080.
[100]Wheeler D C,Bernard D B.Lipid abnormalities in the nephrotic syndrome:causes, consequences, and treatment[J].Am J Kidney Dis, 1994,23(3):331-346.
[101]宋红梅,魏珉.儿童肾病综合征高脂血症的危害及其预防[J].实用儿科临床杂志,2004,19(9)：729-731.
[102]王海燕.肾脏病学[G].人民卫生出版社,2008.
[103]Cho Y J,Lee K E.Decreased glucocorticoid binding affinity to glucocorticoid receptor is important in the poor response to steroid therapy of older-aged patients with severe bronchial asthmafJ].Allergy Asthma Proc,2003,24(5):353-358.
[104]Pujols L, Xaubet A,Ramirez J,et al.Expression of glucocorticoid receptors alpha and beta in steroid sensitive and steroid insensitive interstitial lung diseases[J].Thorax,2004,59(8):687-693.
[105]Raddatz D,Middel P,Bockemuhl M,et al.Glucocorticoid receptor expression in inflammatory bowel disease:evidence for a mucosal down-regulation in steroid-unresponsive ulcerative colitis[J].Aliment Pharmacol Ther,2004,19(1):47-61.
[106]何庆南,易著文,何小解,等.肾病综合征患儿外周血单个核细胞内GRα和GRβ表达的意义[J].中华儿科杂志,2001,39(7)：24-28.
[107]刘宇健,宋亮年,卢建.糖皮质激素对糖皮质激素受体α和β mRNA表达的调节作用[J].中国病理生理杂志,2002,18(3)：243-246.
[108]Vachier I,Roux S.Chanez P,et al.Glucocorticoids nduced down-regulation of glucocorticoid receptor mRNA expression in asthma[J].Clin Exp Immunol,1996,103(2):311-315.
[109]Tamai I,Safa A R.Competitive interaction of cyclosporins with the Vinca alkaloid-binding site of P-glycoprotein in multidrug-resistant cells.[J].Journal of Biological Chemistry,1990,265(27):16509-16513.
[110]Mokrim R,Brunet C,Cazin M,et al.Amisulpride evaluation by radioreceptor assay comparison with HPLC procedure after single administration in the rabbit[J].Methods Find Exp Clin Pharmacol, 1993,15(1):41-47.
[111]McKay L I,Cidlowski J A.Cross-talk between nuclear factor-kappa B and the steroid hormone receptors:mechanisms of mutual antagonism[J]. Mol Endocrinol,1998,12(1):45-56.
[112]McKay L I.Cidlowski J A.Molecular control of immune/inflammatory responses:interactions between nuclear factor-kappa B and steroid receptor-signaling pathways[J].Endocr Rev,1999,20(4):435-459.
[113]McKay L I,Cidlowski J A.CBP(CREB binding protein) integrates NF-kappaB(nuclear factor-kappaB) and glucocorticoid receptor physical interactions and antagonism[J].Mol Endocrinol,2000,14(8):1222-1234.
[114]Seree E,Villard P H.Hever A,et al.Modulation of MDR1 and CYP3A expression by dexamethasone:evidence for an inverse regulation in adrenals[J].Biochem Biophys Res Commun,1998,252(2):392-395.
[115]陆长虹,李杰,郭伟剑,等.大黄素对乳腺癌多药耐药细胞株MCF-7/Adr的耐药逆转作用[J].临床肿瘤学杂志,2004,19(4)：340-343.
[116]Huang X Z,Wang J,Huang C,et al.Emodin enhances cytotoxicity of chemotherapeutic drugs in prostate cancer cells:the mechanisms involve ROS-mediated suppression of multidrug resistance and hypoxia inducible factor-1[J].Cancer Biol Ther,2008,7(3):468-475.
[2]Ross D D. Novel mechanisms of drug resistance in leukemia[J]. Leukemia,2000,14(3):467-473.
[3]Farrell R J,Menconi M J.Keates A C,et al.P-glycoprotein-170 inhibition significantly reduces cortisol and ciclosporin efflux from human intestinal epithelial cells and T lymphocytes[J]. Aliment Pharmacol Ther,2002,16(5):1021-1031.
[4]Stachowski J, Zanker C B, Runowski D, et al. Resistance to therapy in primary nephrotic syndrome:effect of MDR1 gene activity[J]. Pol Merkur Lekarski,2000,8(46):218-221.
[5]Wasilewska A, Zoch-Zwierz W, Pietruczuk M. Expression of multidrug resistance P-glycoprotein on lymphocytes from nephrotic children treated with cyclosporine A and ACE-inhibitor[J]. Eur J Pediatr, 2007,166(5):447-452.
[6]郭向东,邵朝弟,王小琴.邵朝弟教授治疗难治性肾病综合征的临证经验[J].光明中医,2013,28(12)：2502-2504.
[7]武俊斌,顾秀琰.戴恩来教授治疗难治性肾病综合征经验[J].亚太传统医药,2007,27(1)：52-54.
[8]夏海岩,符丹,潘公益,等.沈丕安教授运用金雀根汤治疗难治性肾病综合征的疗效观察[J].四川中医,2013,31(7)：82-84.
[9]李宁,宁静.补肾固精方治疗小儿难治性肾病综合征54例疗效观察[J].中国中西医结合儿科学,2013,5(4)：301-302.
[10]杨少延,庄花.宣肺利水扶正汤治疗难治性肾病综合征水肿28例[J].陕西中医,2012,33(8)：970-971.
[11]雷宏强,丁晓炼,徐薇,等.黄芪五苓散联合激素治疗难治性肾病 综合征疗效观察[J].陕西中医,2012,33(8)：973-974.
[12]孙瑞涛,杨毅勇.补阳还五汤治疗难治性肾病综合征的疗效评价[J].同济大学学报(医学版),2013,34(4)：104-107.
[13]魏连波,陈严文.叶任高教授治疗常复发性肾病综合征的经验[J].中国中西医结合肾病杂志,2011,12(11)：949-950.
[14]张恩,汤水福.汤水福教授标本论治难治性肾病综合征临证撷菁[J].中国中西医结合肾病杂志,2013,14(9)：817-818.
[15]傅玉素,倪青.时振声教授治疗难治性肾病综合征的经验[J].新中医,1998,30(11)：8-9.
[16]刘玉宁,杜兰屏,邓跃毅.陈以平教授治疗膜性肾病的经验[J].中国中西医结合肾病杂志,2004,5(3)：131-132.
[17]董保华,李绍华,袁平.叶传蕙教授治疗难治性肾病综合征经验[J].山西中医,2008,24(8)：6-8.
[18]杨倩春.杨霓芝教授治疗难治性肾病综合征的临床经验[J].中国中西医结合肾病杂志,2003,4(9)：500-502.
[19]沈莲莉,李交,郑蓉,等.灸药并用对难治性肾病综合征患者血清IL-6与IL-8的影响[J].世界中西医结合杂志,2013,8(6)：582-584.
[20]张雪荣,李云海.肾敷灵外敷配合雷公藤多甙对难治性肾病大鼠肾组织炎症因子NF-κB及TGF-β的影响[J].中国中医药现代远程教育2014,12(2)：152-154.
[21]赵学兰,李香玲,郭民,等.益气活血补肾方对难治性肾病综合征患者临床疗效及T淋巴细胞亚群、细胞因子的影响[J].中成药2013,35(8)：1637-1640.
[22]Durkan A, Hodson E M, Willis N S, et al. Non-corticosteroid treatment for nephrotic syndrome in children[J]. the Cochrane library, 2007.
[23]Davutoglu M, Ece A, Bilici M, et al. Steroid Responsiveness of Children with Idiopathic Nephrotic Syndrome in Southeastern Region of Turkey[J]. Renal Failure,2007,29(7):855-859.
[24]McCollum A K, TenEyck C J, Stensgard B, et al. P-Glycoprotein- mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response[J]. Cancer research,2008,68(18):7419-7427.
[25]Palmer S C, Nand K, Strippoli G F. Interventions for minimal change disease in adults with nephrotic syndrome[J]. Cochrane Database Syst Rev,2008,1.
[26]Bai Y, Liu W, Guo Q, et al. Screening for urinary biomarkers of steroid-resistant nephrotic syndrome in children[J]. Experimental and therapeutic medicine,2013,5(3):860-864.
[27]何庆南.糖皮质激素受体亚型与糖皮质激素抵抗关系的研究进展[J].国外医学.泌尿系统分册,2001,21(6)：281-282.
[28]王德杰,刘兴国,张东.糖皮质激素受体的研究进展[J].现代生物医学进展,2010,10(8)：1592-1594.
[29]Stahn C, Lowenberg M, Hommes D W, et al. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists[J]. Molecular and cellular endocrinology,2007,275(1):71-78.
[30]Lewis-Tuffin L J, Cidlowski J A. The physiology of human glucocorticoid receptor beta (hGRbeta) and glucocorticoid resistance[J]. Ann N Y Acad Sci,2006,1069:1-9.
[31]何小解,易著文,党西强,等.GR β在原发性肾病综合征患儿糖皮质激素耐药中的作用[J].中华儿科杂志,2005,43(2)：109-112.
[32]何庆南,易著文,何小解,等.GR β在肾病综合征患儿中的表达及影响因素研究[J].中国病理生理杂志,2002,18(9)：19-22.
[33]邱玲,封其华,赵惠君.原发性肾病综合征患儿外周血GR a、GRβ的表达及临床意义[J].临床儿科杂志,2012,30(4)：332-335.
[34]许冬梅,施惠英,李鹤英,等.原发性肾病综合征患者淋巴细胞糖皮质激素受体及基因测定的意义[J].山东大学学报(医学版),2002,40(4)：297-299.
[35]Hurley D M, Accili D, Stratakis C A, et al. Point mutation causing a single amino acid substitution in the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance[J]. J Clin Invest,1991,87(2):680-686.
[36]Lee Y M, Fujiwara J, Munakata Y, et al. A mutation of the glucocorticoid receptor gene in patients with systemic lupus erythematosus[J]. Tohoku J Exp Med,2004,203(2):69-76.
[37]Charmandari E, Raji A, Kino T, et al. A novel point mutation in the ligand-binding domain (LBD) of the human glucocorticoid receptor (hGR) causing generalized glucocorticoid resistance:the importance of the C terminus of hGR LBD in conferring transactivational activity[J]. J Clin Endocrinol Metab,2005,90(6):3696-3705.
[38]Charmandari E, Kino T, Ichijo T, et al. Functional characterization of the natural human glucocorticoid receptor (hGR) mutants hGRalphaR477H and hGRalphaG679S associated with generalized glucocorticoid resistance[J]. J Clin Endocrinol Metab, 2006,91(4):1535-1543.
[39]Orbak Z. Glucocorticoid resistance[J]. Biochemistry (Mosc), 2006,71(10):1073-1081.
[40]叶建伟,丁洁,黄建萍,等.糖皮质激素受体基因多态性与肾病综合征患儿激素耐药相关性探讨[J].中华儿科杂志,2003,41(9)：25-29.
[41]赵峰,遆新宇,蔡累,等.糖皮质激素受体基因G679S多态性与激素抵抗型哮喘的相关性[J].第四军医大学学报,2009,30(6)：541-544.
[42]赵峰,蔡累,遆新宇,等.糖皮质激素受体基因R477H多态性与激素抵抗型哮喘的相关性[J].临床肺科杂志,2009,14(5)：597-599.
[43]赵峰,刘颖格,遆新宇,等.糖皮质激素受体基因D641V多态性与激素抵抗型哮喘的相关性[A].中国生理学会第23届全国会员代表大会暨生理学学术大会论文摘要文集[c].中国生理学会第23届全国会员代表大会暨生理学学术大会.2010.中国陕西西安：284.
[44]Kang K I, Meng X, Devin-Leclerc J, et al. The molecular chaperone Hsp90 can negatively regulate the activity of a glucocorticosteroid-dependent promoter[J]. Proc Natl Acad Sci USA, 1999,96(4):1439-1444.
[45]欧阳涓,姜傥,谭敏,等.HSP90在原发性肾病综合征发生和治疗中的意义[J].中山大学学报(医学科学版),2006,27(6)：661-666.
[46]Pace T W,Hu F,Miller A H.Cytokine-effects on glucocorticoid receptor function:relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression[J].Brain Behav Immun,2007,21(1):9-19.
[47]黄文彦.原发性肾病综合征糖皮质激素耐药机制研究进展[J].实用儿科临床杂志,2008,23(17)：1315-1318.
[48]Juliano R L,Ling V.A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants[J].Biochim Biophys Acta,1976,455(1):152-162.
[49]Funaki S,Takahashi S.Wada N,et al.Multiple drug-resistant gene 1 in children with steroid-sensitive nephrotic syndrome[J].Pediatr Int,2008,50(2):159-161.
[50]付强,封其华,宋晓翔,等.原发.性肾病综合征患儿外周血单个核细胞多药耐药基因1及P-糖蛋白170的表达[J].实用儿科临床杂志,2010,25(5)：342-344.
[51]Leslie E M,Deeley R G,Cole S P.Multidrug resistance proteins:role of P-glycoprotein, MRP1,MRP2,and BCRP(ABCG2) n tissue defense[J].Toxicol Appl Pharmacol,2005,204(3):216-237.
[52]Mark P J,Waddell B J.P-glycoprotein restricts access of cortisol and dexamethasone to the glucocorticoid receptor in placental BeWo cells[J].Endocrinology,2006,147(11):5147-5152.
[53]王清,刘倩,张学梅.P-糖蛋白及其逆转肿瘤细胞多药耐药性的研究进展[J].中国执业药师,2013,10(3)：33-36.
[54]Hutson J R,Koren G,Matthews S G.Placental P-glycoprotein and breast cancer resistance protein:influence of polymorphisms on fetal drug exposure and physiology[J].Placenta,2010,31 (5):351-357.
[55]闻镍,张双庆,朱凌,等.P-糖蛋白最新研究进展[J].中国药事,2011,25(7)：718-723.
[56]关凤军,易著文,何小解,等.肾病综合征患儿肾组织P-糖蛋白170表达的研究[J].中国实用儿科杂志,2007,22(10)：780-782.
[57]聂吴,王晖.P糖蛋白在不同组织中的分布与功能研究进展[J].广东药学院学报,2012,28(4)：456-460.
[58]Tosi P,Madoulet C.Nicolau C,et al.Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers[Z].Google Patents,2013.
[59]Campone M, Vavasseur F,Le Cabellec M T,et al.Induction of chemoresistance in HL-60 cells concomitantly causes a resistance to apoptosis and the synthesis of P-glycoprotein[J].Leukemia, 2001,15(9):1377-1387.
[60]Mantovani I,Cappellini A,Tazzari P L,et al.Caspase-dependent cleavage of 170-kDa P-glycoprotein during apoptosis of human T-lymphoblastoid CEM cells[J].J Cell Physiol,2006,207(3):836-844.
[61]Ruefli A A,Bernhard D,TaintonKM,et al.Suberoylanilide hydroxamic acid(SAHA) overcomes multidrug resistance and induces cell death in P glycoprotein-expressing cells[J].International journal of cancer, 2002,99(2):292-298.
[62]Jafar T,Prasad N.Agarwal V,et al.MDR-1 gene polymorphisms in steroid-responsive versus steroid-resistant nephrotic syndrome in children[J].NephrologyDialysis Transplantation,2011,26(12):3968-3974.
[63]关凤军,易著文,党西强,等.原发性肾病综合征患儿外周血单个核细胞膜P-糖蛋白170表达的意义[J].实用儿科临床杂志,2011,26(5)：322-324.
[64]关凤军,易著文,党西强,等.肾病综合征患儿外周血单个核细胞内地塞米松浓度与细胞膜表面P-糖蛋白170表达的相关性研究[J].中国循证儿科杂志,2009,4(2)：85-90.
[65]付强,封其华,宋晓翔,等.P-糖蛋白170在原发性肾病综合征患儿糖皮质激素耐药中的作用[J].临床儿科杂志,2010,28(4)：334-337.
[66]王倩涵.阿霉素肾病大鼠MDR1及P-gp170的表达与意义[D].苏州大 学,2013.
[67]Fuchshuber A,Jean G,Gribouval O,et al.Mapping a gene (SRN1) to chromosome 1q25-q31 in idiopathic nephrotic syndrome confirms a distinct entity of autosomal recessive nephrosis[J].Hum Mol Genet, 1995,4(11):2155-2158.
[68]Caridi G.Bertelli R.Carrea A,et al.Prevalence,genetics,and clinical features of patients carrying podocin mutations in steroid-resistant nonfamilial focal segmental glomerulosclerosis[J].J Am Soc Nephrol,2001,12(12):2742-2746.
[69]Karle S M,Uetz B,Ronner V,et al.Novel mutations in NPHS2 detected in both familial and sporadic steroid-resistant nephrotic syndrome[J].J Am Soc Nephrol,2002,13(2):388-393.
[70]Ruf R G,Lichtenberger A,Karle S M,et al.Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome[J].J Am Soc Nephrol,2004,15(3):722-732.
[71]周国平,郭怡清.人类白细胞抗原对肾病综合征临床过程的预测价值[J].中华儿科杂志,1995,33(6)：358-360.
[72]张毓文,林琳,刘晓荣,等.小儿原发性肾病综合征的临床类型与HLA的相关性[J].中华肾脏病杂志,1999,15(3)：52-53.
[73]Attila G,Noyan A,Karabay B A,et al.Apolipoprotein E polymorphism in childhood nephrotic syndrome[J]. Pediatr Nephrol,2002,17(5):359-362.
[74]Hori C,Hiraoka M.Yoshikawa N,et al.Significance of ACE genotypes and medical treatments in childhood focal glomerulosclerosis[J].Nephron,2001,88(4):313-319.
[75]于思明,郭丹丹,宋立群.虫草肾茶方治疗慢性肾衰竭42例临床观察[J].中医药学报,2007,35(06)：44-46.
[76]宋立群,金丽霞,宋业旭.虫草肾茶胶囊治疗糖尿病肾病的临床研究[J].中华中医药学刊,2009,27(04)：679-681.
[77]宋立群,代丽娟.虫草肾茶方对慢性肾衰竭非透析患者微炎症状态的 改善作用[J].中国中西医结合肾病杂志,2008,9(9)：829-831.
[78]于思明,宋立群,郭丹丹,等.虫草‘益肾颗粒治疗维持性血液透析患者微炎症状态临床研究[J].辽宁中医杂志,2013,40(7)：1384-1385.
[79]徐艳秋,宋立群.虫草肾茶方治疗慢性肾脏病不同阶段的临床疗效观察[J].中国中西医结合肾病杂志,2007,8(7)：415-416.
[80]裴春鹏.虫草肾茶胶囊对糖尿病肾病大鼠TGF-β/Smads信号通路影响的实验研究[D].黑龙江中医药大学,2009.
[81]宋立群,金丽霞,宋业旭.虫草肾茶胶囊对肾小球系膜细胞增殖的影响[J].中医药学报,2009,37(3)：21-23.
[82]宋立群,金丽霞,宋业旭.虫草肾茶胶囊对肾小球系膜细胞增殖及分泌Ⅳ型胶原的影响[J].中华中医药学刊,2009,27(9)：1811-1813.
[83]Eddy A A.Plasminogen activator inhibitor-1 and the kidney[J]. Am J Physiol Renal Physiol,2002,283(2):F209-F220.
[84]Schnaper H W.Balance between matrix synthesis and degradations determinant of glomerulosclerosis[J].Pediatr Nephrol,1995,9(1):104-111.
[85]金丽霞,宋立群,马艳春,等.虫草肾茶胶囊对人肾小球系膜细胞TGF-β_1mRNA及PAI-1mRNA表达的影响[J].山西中医,2011,27(5)：44-46.
[86]金丽霞,宋立群,宋业旭.虫草肾茶胶囊对人肾小球系膜细胞分泌转化生长因子β1及细胞外基质的影响[J].中国临床保健杂志,2011,14(3)：287-289.
[87]徐艳秋,宋立群,须冰,等.虫草肾茶对慢性肾衰竭大鼠足细胞中巢蛋白的影响[J].上海中医药杂志,2008,42(10)：73-76.
[88]马晓鹏,宋立群,于思明,等.虫草肾茶颗粒对单侧输尿管结扎大鼠肾间质纤维化模型CTGFmRNA的影响[J].中国临床保健杂志,2010,13(3)：271-274.
[89]于思明,郭丹丹,马艳春,等.虫草益肾颗粒对5/6肾切除大鼠残肾组织α-平滑肌肌动蛋白表达的影响[J].中国临床保健杂志,2010,13(3)：283-285.
[90]宋立群,于思明,郭丹丹,等.虫草肾茶胶囊对5/6肾切除大鼠残肾组织 MMP-2与TIMP-1表达的影响[J].辽宁中医杂志,2009,36(11)：1860-1862.
[91]宋立群,于思明,郭丹丹,等.虫草肾茶胶囊对肾小球硬化早期模型大鼠细胞外基质积聚的影响[J].中国临床保健杂志,2009,12(4)：397-399.
[92]宋立群,于思明,郭丹丹,等.虫草肾茶胶囊对肾小球硬化早期模型大鼠肾脏组织形态学的影响[J].中华中医药学刊,2009,27(10)：2037-2040.
[93]Border W A,Harry J W,Kamil E S,et al.Induction of membranous nephropathy in rabbits by administration of an exogenous cationic antigen:demonstration of a pathogenic role for electrical charge[J].Journal of Clinical Investigation,1982,69(2):451-461.
[94]陈永兴,张秋业.激素耐药型肾病综合征发病机制及治疗对策研究进展[J].实用儿科临床杂志,2006,21(19)：1346-1348.
[95]邢昌赢.KDIGO指南解读：特发性膜性肾病治疗[J].中国实用内科杂志,2012,32(12)：928-931.
[96]刘伏友.蛋白尿致肾小管间质纤维化的机制及防治[J].中华肾脏病杂志,2006,22(5)：258-260.
[97]Theilig F.Spread of glomerular to tubulointerstitial disease with a focus on proteinuria[J].Annals of Anatomy-Anatomischer Anzeiger, 2010,192(3):125-132.
[98]于思明.虫草肾茶胶囊对肾小球硬化模型大鼠ECM积聚与TIMP-1mRNA表达的影响[D].黑龙江中医药大学,2008.
[99]Demant T,Mathes C,Gutlich K,et al.A simultaneous study of the metabolism of apolipoprotein B and albumin in nephrotic patients[J]. Kidney Int,1998,54(6):2064-2080.
[100]Wheeler D C,Bernard D B.Lipid abnormalities in the nephrotic syndrome:causes, consequences, and treatment[J].Am J Kidney Dis, 1994,23(3):331-346.
[101]宋红梅,魏珉.儿童肾病综合征高脂血症的危害及其预防[J].实用儿科临床杂志,2004,19(9)：729-731.
[102]王海燕.肾脏病学[G].人民卫生出版社,2008.
[103]Cho Y J,Lee K E.Decreased glucocorticoid binding affinity to glucocorticoid receptor is important in the poor response to steroid therapy of older-aged patients with severe bronchial asthmafJ].Allergy Asthma Proc,2003,24(5):353-358.
[104]Pujols L, Xaubet A,Ramirez J,et al.Expression of glucocorticoid receptors alpha and beta in steroid sensitive and steroid insensitive interstitial lung diseases[J].Thorax,2004,59(8):687-693.
[105]Raddatz D,Middel P,Bockemuhl M,et al.Glucocorticoid receptor expression in inflammatory bowel disease:evidence for a mucosal down-regulation in steroid-unresponsive ulcerative colitis[J].Aliment Pharmacol Ther,2004,19(1):47-61.
[106]何庆南,易著文,何小解,等.肾病综合征患儿外周血单个核细胞内GRα和GRβ表达的意义[J].中华儿科杂志,2001,39(7)：24-28.
[107]刘宇健,宋亮年,卢建.糖皮质激素对糖皮质激素受体α和β mRNA表达的调节作用[J].中国病理生理杂志,2002,18(3)：243-246.
[108]Vachier I,Roux S.Chanez P,et al.Glucocorticoids nduced down-regulation of glucocorticoid receptor mRNA expression in asthma[J].Clin Exp Immunol,1996,103(2):311-315.
[109]Tamai I,Safa A R.Competitive interaction of cyclosporins with the Vinca alkaloid-binding site of P-glycoprotein in multidrug-resistant cells.[J].Journal of Biological Chemistry,1990,265(27):16509-16513.
[110]Mokrim R,Brunet C,Cazin M,et al.Amisulpride evaluation by radioreceptor assay comparison with HPLC procedure after single administration in the rabbit[J].Methods Find Exp Clin Pharmacol, 1993,15(1):41-47.
[111]McKay L I,Cidlowski J A.Cross-talk between nuclear factor-kappa B and the steroid hormone receptors:mechanisms of mutual antagonism[J]. Mol Endocrinol,1998,12(1):45-56.
[112]McKay L I.Cidlowski J A.Molecular control of immune/inflammatory responses:interactions between nuclear factor-kappa B and steroid receptor-signaling pathways[J].Endocr Rev,1999,20(4):435-459.
[113]McKay L I,Cidlowski J A.CBP(CREB binding protein) integrates NF-kappaB(nuclear factor-kappaB) and glucocorticoid receptor physical interactions and antagonism[J].Mol Endocrinol,2000,14(8):1222-1234.
[114]Seree E,Villard P H.Hever A,et al.Modulation of MDR1 and CYP3A expression by dexamethasone:evidence for an inverse regulation in adrenals[J].Biochem Biophys Res Commun,1998,252(2):392-395.
[115]陆长虹,李杰,郭伟剑,等.大黄素对乳腺癌多药耐药细胞株MCF-7/Adr的耐药逆转作用[J].临床肿瘤学杂志,2004,19(4)：340-343.
[116]Huang X Z,Wang J,Huang C,et al.Emodin enhances cytotoxicity of chemotherapeutic drugs in prostate cancer cells:the mechanisms involve ROS-mediated suppression of multidrug resistance and hypoxia inducible factor-1[J].Cancer Biol Ther,2008,7(3):468-475.